ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,420.26
-0.22%
Dow Jones
40,003.59
0.34%
Gold vs US Dollar
2,415.36
1.56%
Brent Oil
83.715
0.61%
Bitcoin
66,881.05
2.52%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Catalyst Pharmaceuticals Inc (CPRX)

  7. Catalyst Pharmaceuticals Inc (CPRX) News

Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CPRX
DateTimeSourceHeadlineSymbolCompany
08/05/202421:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
08/05/202421:16GlobeNewswire Inc.Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CPRXCatalyst Pharmaceuticals Inc
08/05/202421:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
01/05/202413:00GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
22/04/202413:00GlobeNewswire Inc.Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
28/03/202412:03GlobeNewswire Inc.Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness DayNASDAQ:CPRXCatalyst Pharmaceuticals Inc
27/03/202412:03GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy SymposiumNASDAQ:CPRXCatalyst Pharmaceuticals Inc
13/03/202411:55GlobeNewswire Inc.Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)NASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/03/202413:03GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:CPRXCatalyst Pharmaceuticals Inc
28/02/202423:03GlobeNewswire Inc.Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CPRXCatalyst Pharmaceuticals Inc
27/02/202413:03GlobeNewswire Inc.Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREENASDAQ:CPRXCatalyst Pharmaceuticals Inc
21/02/202414:00GlobeNewswire Inc.Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal NeurologyNASDAQ:CPRXCatalyst Pharmaceuticals Inc
16/02/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
16/02/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
16/02/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
16/02/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
16/02/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
16/02/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
16/02/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
14/02/202413:03GlobeNewswire Inc.Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
09/01/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
09/01/202421:05GlobeNewswire Inc.Catalyst Pharmaceuticals, Inc. Announces Closing of Public OfferingNASDAQ:CPRXCatalyst Pharmaceuticals Inc
08/01/202413:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/01/202422:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/01/202422:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/01/202413:02GlobeNewswire Inc.Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockNASDAQ:CPRXCatalyst Pharmaceuticals Inc
04/01/202421:49GlobeNewswire Inc.Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockNASDAQ:CPRXCatalyst Pharmaceuticals Inc
03/01/202422:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
03/01/202422:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
03/01/202422:18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CPRX

Your Recent History

NASDAQ
PRSRU
Prospector Capital
LSE
IPRT
Invesco Perp Recovery 2011
LSE
12YR
Sg Issuer 24
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved